Harlan Krumholz/LinkedIn
Dec 11, 2025, 12:50
Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
Harlan Krumholz, Harold H. Hines Jr. Professor at Yale University, shared on LinkedIn:
”Clinical trials rarely come with expiration dates.
Yet the patients we treat today are not the same as those studied 40 years ago.
New trials on beta blockers after myocardial infarction highlight how much cardiology has changed, and how slowly our evidence adapts.
This is not simply about one therapy.
It is about the half-life of evidence and the need for modern, pragmatic, real-time trials that keep pace with evolving practice.
I explored this in my latest piece.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke